SNOA
NASDAQ · Pharmaceuticals
Sonoma Pharmaceuticals Inc
$2.36
+0.02 (+0.85%)
Financial Highlights (FY 2026)
Revenue
20.17M
Net Income
-4,881,231
Gross Margin
38.2%
Profit Margin
-24.2%
Rev Growth
+4.2%
D/E Ratio
0.05
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 38.2% | 38.2% | 35.0% | 35.0% |
| Operating Margin | -26.0% | -23.4% | 23.2% | 24.4% |
| Profit Margin | -24.2% | -23.0% | 25.4% | 21.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 20.17M | 19.36M | 1.82M | 1.63M |
| Gross Profit | 7.72M | 7.41M | 638.4K | 569.1K |
| Operating Income | -5,239,221 | -4,525,238 | 423.5K | 396.5K |
| Net Income | -4,881,231 | -4,216,034 | 463.1K | 348.9K |
| Gross Margin | 38.2% | 38.2% | 35.0% | 35.0% |
| Operating Margin | -26.0% | -23.4% | 23.2% | 24.4% |
| Profit Margin | -24.2% | -23.0% | 25.4% | 21.5% |
| Rev Growth | +4.2% | +4.2% | -7.1% | +16.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 99.9K | 99.9K | 821.0K | 810.3K |
| Total Equity | 2.00M | 2.00M | 2.76M | 3.02M |
| D/E Ratio | 0.05 | 0.05 | 0.30 | 0.27 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -4,252,875 | -3,877,381 | 609.2K | 511.6K |
| Free Cash Flow | — | — | 381.4K | 338.4K |